BSD Medical Reports Presentation of Cochrane Review on the Use of Hyperthermia in Cervical Cancer Treatment at ESHO 2010 M

SALT LAKE CITY--(BUSINESS WIRE)-- BSD Medical Corporation (NASDAQ: BSDM) today reported significant clinical results from the use of hyperthermia to treat cervical cancer. The results were presented at the annual meeting of the European Society for Hyperthermic Oncology (ESHO), which was held in Rotterdam, The Netherlands, on May 19 to 21, 2010.

Dr. L. Lutgens, Maastricht University Medical School, The Netherlands, presented the results of a Cochrane Review, “Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma (Review).” The researchers concluded that “Available data do suggest that the addition of hyperthermia improves local tumour control and overall survival in patients with locally advanced cervical carcinoma without affecting treatment related grade 3 to 4 acute or late toxicity.”

The Cochrane Review analyzed six randomized controlled studies on the combined use of regional hyperthermia (RHT) and radiation therapy for treating locally advanced cervical carcinoma. The data demonstrated that “Using overall survival at three years as endpoint in the pooled data analysis including 264 study patients yielded a significantly better survival for the combined treatment group (RHT) (HR 0.67; 95% CI 0.45 to 0.99; p = 0.05).” The data also showed a significant reduction in local recurrence of disease at three years. There was no difference in either short-term or long-term toxicity from the addition of hyperthermia to radiation therapy.

Dr. A. Westermann, Academic Medical Center, Amsterdam, The Netherlands, further reported long-term results from a clinical study on the use of radiation therapy, chemotherapy (cisplatin) and hyperthermia to treat patients with advanced cervical cancer. The presentation, “Long-term follow-up of a Phase II feasibility study of regional hyperthermia added to chemoradiotherapy in advanced cervical cancer,” reported data for 36 patients who had a median follow-up of 62 months (range 6-97 months). The five-year disease-free survival rate was 66% (95% CI: 52-84), and the overall survival rate was 74% (95% CI: 60-90). A Phase III study has been initiated.

About the Cochrane Review

The Cochrane Collaboration is an international, independent, not-for-profit organization of over 27,000 contributors from more than 100 countries. The organization publishes systematic assessments of healthcare interventions, known as “Cochrane Reviews,” which are the most comprehensive, reliable and relevant source of evidence on which to base treatment decisions. The Cochrane organization is a world leader in evidence-based health care decisions.

About the European Society for Hyperthermic Oncology

ESHO was organized to promote research relating to the use of hyperthermia in cancer therapy and to facilitate the exchange of information among multiple disciplines regarding the study of heat in the treatment of cancer.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radio frequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system, which the Company will introduce to the market this year, has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China. The BSD-2000 is restricted to investigational use in the US. For further information visit BSD Medical's website at

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.


BSD Medical Corporation, Salt Lake City
Dennis Gauger, 801-972-5555
Fax: 801-972-5930
[email protected]

KEYWORDS:   United States  Europe  North America  Netherlands  Utah

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Hospitals  Medical Devices  Oncology  Radiology  Other Health  FDA